Italian journal review says oral semaglutide failed to slow early Alzheimer decline

The wire

1. 01A review in Recenti Progressi in Medicina summarizes two trials of oral semaglutide in early Alzheimer disease and concludes the drug did not slow cognitive decline.
2. 02The negative result cuts against the hypothesis that incretin signaling protects the brain, and clinicians fielding patient questions about GLP-1s for dementia now have a clear answer.
3. 03The item is a journal commentary rather than the primary trial publication; readers should check the underlying trial reports for endpoint definitions, dose and follow-up duration.

From the source

[Two trials, one result: oral semaglutide does not slow cognitive decline in early Alzheimer disease.]

Recenti progressi in medicina · 2026 Oct · Kurotschka PK, Barry H et al.